In an in vitro model of Parkinson's disease, COX-2 inhibitors showed a dramatically reduced level of neuroprotection towards dopaminergic neurons in cultures that lack microglia following MPP+ (1-methyl-4-phenylpyridinium)-induced death [42]. Here, PTGS2 is linked to Parkinson disease.